New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:52 EDTMNOVMedicNova announces positive results of MN-001 in advanced NASH mouse model
MediciNova announced positive results from a second preclinical study that examined the potential clinical efficacy of MN-001 for the treatment of advanced NASH, or nonalcoholic steatohepatitis with fibrosis. This study used mice in more advanced stages of NASH as compared to the first study of MN-001 in a NASH mouse model. MN-001 administered orally once daily for 4 weeks, was evaluated in the STAM mouse model of advanced NASH, as measured by histopathology, NAFLD activity score, or NAS, and percent of fibrosis. MN-001 showed anti-NASH and anti-fibrotic effects in the advanced NASH mouse model. NAFLD activity score was significantly reduced in the MN-001 treated group compared to the non-treated group. The reduction was observed consistently in all NAS components including hepatocyte ballooning score, lobular inflammation score, and steatosis score. Percent fibrosis area was also reduced in the MN-001 treated group. In addition, alpha-SMA-positive staining area was significantly reduced in the MN-001 treated group. Based on these results in addition to the results of the first NASH mouse model study reported on January 14, MediciNova requested a meeting with FDA to finalize the trial design for a clinical study of MN-001 in NASH patients.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
18:04 EDTMNOVMediciNova receives allowance of patent covering MN-001and MN-002
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use